A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or
The risk of developing ankylosing spondylitis (AS) if you are HLA-B27+ and a first degree relative is often said to be 20%.
Turina et al. set out to assess the risk of seemingly healthy first-degree relatives of AS based on whether they develop clinical, laboratory, or imaging features of spondyloarthritis (SpA).
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
Up to half of women on AI therapy experience joint pain, and up to 20% become non-compliant with their AI therapy because of joint pain. (Citation source http://buff.ly/2dQNpfy)
The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.In preparation for World Osteoporosis Day the IOF wishes to spread this "urgent call to action".
The diagnosis of periodic fevers is unified by undiagnosed but recurrent fever. Unfortunately the diagnosis of these disorders is hampered by their infrequency, protean features and a lack of clear criteria. Even more problematic is knowing who should be tested and for which monogenic marker?
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.
In the United States, arthritis is a leading cause of disability and affects an estimated 52.5 million (22.7%) adults in 2010–2012; it has been projected to rise to 78.4 million adults by 2040.
RheumNow will periodically review this subject with “Biosimilar Reports” providing updates, news, new publications, overview articles and research results impacting to biosimilar development and use.
Muscle involvement in immune-mediated necrotizing myopathy (IMNM) was more extensive compared with other inflammatory myopathies, according to a retrospective chart review.
Children with juvenile idiopathic arthritis (JIA) treated with biologic therapies were at no higher risk for hospitalized infections than those treated with methotrexate alone, But, higher rates were seen with anakinra in systemic JIA.
Singh and colleagues have published a systematic review and Bayesian network metaanalyses of clinical trials of immunosuppressive drugs and corticosteroids in patients with lupus nephriti.
Symptoms attributed to chronic Lyme disease are the bane of a rheumatologist’s existence. We often see patients referred for a variety of nonspecific complaints that do not resolve after antibiotic therapy, including the so-called post-Lyme disease syndrome.
There are, however, a variety of musculoskeletal complaints that may occur in the wake of Lyme disease and sometimes the picture is not so clear.
A Wall Street Journal article claims that U.S. drugmakers are pointing the blame at the middlemen who also influence drug priciing.
